Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice.
Coxsackievirus B3 (CVB3) is an important cause of acute and chronic viral myocarditis, and dilated cardiomyopathy (DCM). Although vaccination against CVB3 could significantly reduce the incidence of serious or fatal viral myocarditis and various other diseases associated with CVB3 infection, there is currently no vaccine or therapeutic reagent in clinical use. In this study, we contributed towards the development of a CVB3 vaccine by establishing an efficient and scalable ion exchange chromatography-based purification method for CVB3 virus and baculovirus-insect cell-expressed CVB3 virus-like particles (VLPs). This purification system is especially relevant for vaccine development and production on an industrial scale. The produced VLPs were characterized using a number of biophysical methods and exhibited excellent quality and high purity. Immunization of mice with VLPs elicited a strong immune response, demonstrating the excellent vaccine potential of these VLPs.
BioMediTech, University of Tampere and Tampere University Hospital, Biokatu 6, FI-33014 University of Tampere, Finland.
Tiia
T
Koho
Vactech Ltd, Biokatu 8, FI-33520 Tampere, Finland.
Minni R L
MR
Koivunen
Department of Virology, School of Medicine, Biokatu 10, FI-33014 University of Tampere, Finland.
Sami
S
Oikarinen
School of Medicine, FI-33014 University of Tampere, Finland; Fimlab Laboratories, Pirkanmaa Hospital District, Biokatu 4, FI-33520 Tampere, Finland.
Laura
L
Kummola
BioMediTech, University of Tampere and Tampere University Hospital, Biokatu 6, FI-33014 University of Tampere, Finland.
Selina
S
Mäkinen
BioMediTech, University of Tampere and Tampere University Hospital, Biokatu 6, FI-33014 University of Tampere, Finland.
Anssi J
AJ
Mähönen
Department of Virology, School of Medicine, Biokatu 10, FI-33014 University of Tampere, Finland.
Amirbabak
A
Sioofy-Khojine
Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, P.O. Box 35, FI-40014 University of Jyväskylä, Finland.
Varpu
V
Marjomäki
Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, P.O. Box 35, FI-40014 University of Jyväskylä, Finland.
Artur
A
Kazmertsuk
School of Medicine, FI-33014 University of Tampere, Finland; Fimlab Laboratories, Pirkanmaa Hospital District, Biokatu 4, FI-33520 Tampere, Finland.
Ilkka
I
Junttila
BioMediTech, University of Tampere and Tampere University Hospital, Biokatu 6, FI-33014 University of Tampere, Finland.
Markku S
MS
Kulomaa
Department of Virology, School of Medicine, Biokatu 10, FI-33014 University of Tampere, Finland; School of Medicine, FI-33014 University of Tampere, Finland; Fimlab Laboratories, Pirkanmaa Hospital District, Biokatu 4, FI-33520 Tampere, Finland.
Heikki
H
Hyöty
BioMediTech, University of Tampere and Tampere University Hospital, Biokatu 6, FI-33014 University of Tampere, Finland; Fimlab Laboratories, Pirkanmaa Hospital District, Biokatu 4, FI-33520 Tampere, Finland.
Vesa P
VP
Hytönen
Vactech Ltd, Biokatu 8, FI-33520 Tampere, Finland; The Center for Infectious Medicine, Department of Medicine HS, Karolinska Institutet, Karolinska University Hospital Huddinge F59, SE-141 86 Stockholm, Sweden. Electronic address: olli.laitinen@ki.se.
Olli H
OH
Laitinen
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000918:Antibody Specificity; D016367:Baculoviridae / Q000235:genetics; D002852:Chromatography, Ion Exchange; D003384:Coxsackievirus Infections / Q000276:immunology* / Q000517:prevention & control; D004195:Disease Models, Animal; D029822:Enterovirus B, Human / Q000276:immunology*; D005260:Female; D023061:Gene Order; D005822:Genetic Vectors / Q000235:genetics; D007111:Immunity, Cellular; D007114:Immunization; D051379:Mice; D058425:Vaccines, Virus-Like Particle / Q000276:immunology* / Q000302:isolation & purification / Q000648:ultrastructure
D000914:Antibodies, Viral; D058425:Vaccines, Virus-Like Particle
CVB3; Ion exchange chromatography; VLP